Pharmaceutical investment promotion companies are as important as developing themselves and developing enterprises.

In order to obtain better results in attracting investment, pharmaceutical investment promotion should have the right to negotiate with upstream manufacturers to obtain as many good products as possible, and it must also work hard on its own core competitiveness. Enterprises take products as the prerequisite for marketing, and pharmaceutical investment companies are even more so. In the business process of the investment enterprise, creating a star product and star market of the enterprise is the core of whether the enterprise can have a breakthrough in development. For investment enterprises, after years of accumulation and precipitation, each enterprise has many agents and customer resources. Many of them are customers who have cooperated with companies for many years and have high loyalty. This is the basis for the survival of pharmaceutical investment enterprises.

The cost of developing a new customer is ten times the cost of maintaining an old customer. The fact that more than 95% of the sales volume of the pharmaceutical investment enterprise is provided by an old customer proves that how to let an old customer increase sales is an important task for the company. . While doing a good job of managing old customers, another aspect of the development of investment enterprises is the development of new customers. It can be said that which pharmaceutical investment enterprise has a stronger ability to develop new customers, then the company's sales and profits will be more secure. In the past few years, advertisements for investment promotion enterprises of pharmaceutical companies were king. As long as media campaigns are well done, a large number of agents will take the initiative to seek product agents. However, nowadays, with the unprecedented prosperity of the media and the more sensible agents, if media information is not published accurately, the effect is not good, and resources are wasted.

As a mode of operation with low investment and high returns in the pharmaceutical industry, pharmaceutical investment has always been a favorite of many companies. However, due to various drawbacks and problems in attracting investment, whether investment promotion has a future, how can we recruit good merchants to increase investment in pharmaceutical investment companies, and other issues have always been discussed by many companies. Nowadays, the new medical reform system is systematically graduating from the experimental trend to the gradual emergence of the industry trend. Several core contents of the pharmaceutical industry's three terminals that are about to change are also enough to attract the attention of pharmaceutical investment enterprises: “public hospital reform” in clinical channels, the third terminal market The "essential drug system" and OTC channels faced the policy squeeze of the former two in the context of the marketization after the Ministry of Commerce took over.

“In order to be heroic after a troubled world,” in the face of the current great changes in the pharmaceutical industry today, timely adjustment of investment strategies and corresponding investment enterprises in accordance with the development of the industry will have the opportunity to seek a better market position and business after the development of the industry in the future. Performance. The most essential difference between the pharmaceutical industry and other industries is its professionalism. We not only need to consider the product and channel adaptation and marketing issues that need to be planned, but also practically consider the issues of patient drug safety and effectiveness. Formally because of this, all problems faced by pharmaceutical investment enterprises are how to make the company itself more professional and can highlight its own core competitiveness.

The three channels through which pharmaceutical investment companies invest in pharmaceuticals are the companies whose core products are OTC products, such as Harbin Pharmaceuticals and Corrections. Although this is related to the fact that China currently does not allow prescription drugs to be advertised in the mass media, we see that after taking the brand recognition of the market, the companies that follow the OTC branding strategy can quickly go to the market and obtain good results. Sales volume is a good illustration of the huge benefits that the branding process has brought to these companies.